Advanced Search

Study Preview



Study Title and Description

Effects of oligofructose-enriched inulin on intestinal absorption of calcium and magnesium and bone turnover markers in postmenopausal women.



Key Questions Addressed
1 Is this an intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Effects of oligofructose-enriched inulin on intestinal absorption of calcium and magnesium and bone turnover markers in postmenopausal women.
Author Holloway L., Moynihan S., Abrams SA., Kent K., Hsu AR., Friedlander AL.
Country Clinical Studies Unit and Geriatric Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, California, USA.
Year 2007
Numbers Pubmed ID: 17298707

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 4.1
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
pubyear 2006
  • Comments Comments (
    0
    ) |
country United States
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (Crossover)
  • Comments Comments (
    0
    ) |
blindness Double blind
  • Comments Comments (
    0
    ) |
diet Unspecified
  • Comments Comments (
    0
    ) |
feedcontrol Packets provided
  • Comments Comments (
    0
    ) |
sampsize 15
  • Comments Comments (
    0
    ) |
runin No
  • Comments Comments (
    0
    ) |
washout Yes
  • Comments Comments (
    0
    ) |
dosechange No
  • Comments Comments (
    0
    ) |
age_adult 1
  • Comments Comments (
    0
    ) |
age_adol
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean 72.2
  • Comments Comments (
    0
    ) |
age_range NR
  • Comments Comments (
    0
    ) |
bmi_mean 25.2
  • Comments Comments (
    0
    ) |
bmi_range NR
  • Comments Comments (
    0
    ) |
blhealth_healthy 1
  • Comments Comments (
    0
    ) |
blhealth_hyperlip
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth 1
  • Comments Comments (
    0
    ) |
blhealth_othspec 10 years post-menopausal
  • Comments Comments (
    0
    ) |
gender 0
  • Comments Comments (
    0
    ) |
ftype1 Oligofructose-Enriched Inulin (Of-In)
  • Comments Comments (
    0
    ) |
descrip1_1
  • Comments Comments (
    0
    ) |
descrip1_2
  • Comments Comments (
    0
    ) |
dose1_1 5
  • Comments Comments (
    0
    ) |
dose1_2
  • Comments Comments (
    0
    ) |
duration1 6 weeks
  • Comments Comments (
    0
    ) |
admin1 Powder
  • Comments Comments (
    0
    ) |
ftype2
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2
  • Comments Comments (
    0
    ) |
admin2
  • Comments Comments (
    0
    ) |
ftype3
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3
  • Comments Comments (
    0
    ) |
admin3
  • Comments Comments (
    0
    ) |
ftype4
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4
  • Comments Comments (
    0
    ) |
admin4
  • Comments Comments (
    0
    ) |
comparator1 Completely digestible maltodextrin
  • Comments Comments (
    0
    ) |
cdose1 0
  • Comments Comments (
    0
    ) |
cduration1 6 weeks
  • Comments Comments (
    0
    ) |
cadmin1 Powder
  • Comments Comments (
    0
    ) |
comparator2
  • Comments Comments (
    0
    ) |
cdose2
  • Comments Comments (
    0
    ) |
cduration2
  • Comments Comments (
    0
    ) |
cadmin2
  • Comments Comments (
    0
    ) |
comparator3
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3
  • Comments Comments (
    0
    ) |
cadmin3
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.